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Abstract
Background: To evaluate the incidence and risk factors of contrast-induced nephropathy (CIN) in patients undergoing
fluorescein angiography (FA).
Methods: One hundred sixty patients who underwent FA as a part of ophthalmic examination and had serum
creatinine (SCr) results within 24 h before FA and within 72 h after FA between 2005 and 2013 at a tertiary
medical center were included. According to baseline SCr levels, the subjects were divided into low-risk group
(<1.5 mg/dL), intermediate-risk group (1.5–2.0 mg/dL), and high-risk group (>2.0 mg/dL) for CIN development.
The CIN incidence, and changes in renal function defined by SCr levels and estimated glomerular filtration
rate (eGFR) were evaluated. Demographics and comorbidities were analyzed to investigate an association with
CIN development.
Results: Of 160 patients, 91 were males (56.9%). The mean age was 52.46 ± 17.81 years. Two (1.3%) patients
developed CIN after FA, whose SCr levels returned to normal within 10 days without hemodialysis. Overall, there were
no changes before and after FA in SCr level (1.52 ± 1.31 mg/dL vs. 1.51 ± 1.28 mg/dL, respectively; p = 0.93) and eGFR
(67.02 ± 36.62 mL/min/1.73 m2 vs. 66.41 ± 36.54 mL/min/1.73 m2, respectively; p = 0.54). SCr level and eGFR remained
unchanged after FA in low-risk and intermediate-risk groups. In high-risk group, eGFR remined unchanged, but
SCr level decreased after FA (from 3.64 ± 1.59 mg/dL to 3.53 ± 1.60 mg/dL; p = 0.04). Basline SCr and cormorbidities did
not predict CIN development.
Conclusions: Acute renal function deterioration was not evident in patients undergoing FA regardless of baseline
renal function and comorbidities.
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Background
Fundus fluorescein angiography (FA) is a crucial imaging
tool in the diagnosis and management of various retinal
diseases including diabetic retinopathy, age-related macu-
lar degeneration, and uveitis. Adverse reactions are usually
mild and transient, but may include serious reactions such
as anaphylaxis, seizures, and death [1–6]. Sodium fluores-
cein (C20H12O5Na, molecular weight 376.27 g/mol), a
noniodinated contrast media used in FA is largely elimi-
nated by the kidneys within 24 h, [7] so patients with renal
insufficiency may be at increased risk of nephrotoxicity
after FA. Common practice may dictate the avoidance of
FA in patients with renal insufficiency, but patients who
require FA imaging for conditions such as diabetic retin-
opathy often have concurrent kidney problems [8, 9].
Contrast-induced nephropathy (CIN) is a form of
acute kidney injury defined by acute elevation of serum
creatinine (SCr), generally within 72 h after the injection
of contrast medium. CIN has been known to increase
the cost of medical care, duration of hospital stay, and risk
of serious long-term adverse events such as permanent
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renal impairment, myocardial infarction, pulmonary
edema, stroke, and death [10]. CIN has received increasing
attention in patients undergoing percutaneous coronary
angiography or contrast-enhanced computed tomography
(CT) scans [10, 11]. Known risk factors for CIN include
older age, diabetes mellitus (DM), pre-existing renal failure,
heart failure, higher volumes of injected contrast media,
dehydration, and concurrent nephrotoxic drugs [11].
However, CIN in the ophthalmological field has not been
investigated, yet; PubMed search (keywords: contrast-
induced nephropathy and fluorescein angiography) showed
no report on CIN associated with FA. We conducted a
retrospective study to investigate whether FA is associated
with the deterioration of acute renal function and deter-
mine the CIN occurrece rate and associated risk factors.
Methods
Medical records for all patients seen at the Department
of Ophthalmology, Severance Hospital, College of Medicine,
Yonsei University between November 2005 and October
2013 were screened retrospectively. This study was
approved by the Institutional Review Board of Severance
hospital (IRB No.4-2014-0799) and was conducted in
accordance with the Declaration of Helsinki.
Patients were included if they had: (a) undergone FA
between November 1, 2005 and October 31, 2013 (b)
baseline SCr results within 24 h before FA (c) SCr
results within 72 h after FA. Exclusion criteria included
pre-existing medical conditions requiring renal dialysis
and having undergone concurrent CT scans or percutan-
eous angiography using contrast media within two weeks
before FA [12]. If there were two or more post-FA SCr
levels available within 72 h after FA, the highest SCr
level was selected.
Predisposing medical/ophthalmologic conditions that
are known to be risk factors for CIN were identified
using International Classification of Diseases, Tenth
Edition, Clinical Modification (ICD-10), which included
diabetic nephropathy (DMN), congestive heart failure
(HF), and chronic kidney disease (CKD). The diagnosis
of CKD was confirmed using conventional criteria
(estimated glomerular filtration rate (eGFR) < 60 mL/min/
1.72 m2) [11, 13–15]. eGFR was calculated using the
Modification of Diet in Renal Disease formula and
included serum albumin and blood urea nitrogen levels.
Patients were stratified according to baseline SCr level
as follows: low-risk group (SCr < 1.5 mg/dL), intermediate-
risk group (SCr 1.5–2.0 mg/dL) and high-risk group
(SCr > 2.0 mg/dL) [16–18].
CIN was defined as a rise in SCr level of 0.5 mg/dL or
greater or as a 25% increase over baseline level within
72 h after FA [19, 20]. In the present study, a rise in SCr
level of 0.5 mg/dL was chosen as a threshold value over
0.3 mg/dL, which was recently proposed by the Acute
Kidney Injury Network, because higher value is poten-
tially more specific, less likely to yield false-positive
results from cumulative biologic and assay variability,
and more commonly used as a definition of CIN in
current medical practice [17, 19, 21, 22].
All patients received 500 mg of sodium fluorescein
(Novartis, Basel, Switzerland) intravenously through an
antecubital vein in 5–8 s. Statistical analyses were per-
formed using R software (version 2.15, R Foundation for
Statistical Computing, Vienna, Austria). A paired student’s
t test and Wilcoxon signed rank test were used to
compare SCr between various groups; all p values of <0.05
were considered statistically significant.
Results
A total of 160 patients (91 male, 69 female) were lin-
cluded. The mean age was 52.46 ± 17.81 years. The demo-
graphic information and clinical findings are presented in
Table 1. Post-FA SCr and eGFR were obtained within 24 h
after FA in 96 patients (60.0%), between 24 and 48 h in 42
patients (26.3%), and between 48 and 72 h in 22 patients
(13.7%). Baseline SCr level was 1.52 ± 1.31 mg/dL, and
baseline eGFR was 67.02 ± 36.62 mL/min/1.73 m2. There
were no changes in SCr level and eGFR after FA.
When patients were grouped according to their
baseline SCr levels, there were no changes in SCr
level and eGRF after FA in low-risk group and
intermediate-risk group. In high-risk group, SCr level
decreased after FA, while there was no change in eGFR
(Table 1). SCr levels and eGFR remained unchanged after
FA when they were analyzed according to coexisting
medical/ophthalmologic conditions that are known risk
factors of CIN (Table 2). SCr levels and eGFR did not
change after FA regardless of whether patients were
inpatients or outpatients (Table 3).
Of 160 patients, 2 (1.3%) patients developed CIN, 1 in
the low-risk group and 1 in the intermediate-risk group
(Table 4). Patient number 1 was a 53-year-old male with
underlying hypertension. He was admitted to the oph-
thalmology department due to bilateral acute syphilitic
posterior placoid chorioretinitis. His SCr level increased
from 0.84 mg/dL to 2.08 mg/dL 24 h after FA; however,
SCr level decreased rapidly and was normalized to base-
line level (0.81 mg/dL) within 3 days without treatment.
Patient number 2 was a 62-year-old diabetic male. He
was admitted due to sphenoethmoidal aspergillosis and
was evaluated in ophthalmological department for
decreased visual acuity. His SCr level increased by
0.8 mg/dL after FA (1.5 mg/dL to 2.3 mg/dL) within
72 h. Nephrologist suspected amphotericin-related ne-
phropathy and changed systemic medication from
amphotericin B to voriconazole. His SCr level decreased
to baseline level (1.7 mg/dL) within 10 days.
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Discussion
There were no significant changes in SCr levels and
eGFR after FA in patients with various baseline SCr
levels. In the high-risk group, SCr levels actually decreased
following FA, but this change is clinically insignificant, as
a reduction in SCr after FA may not indicate improvement
in renal function. Female gender has been identified as an
independent risk factor for CIN [23]. The relatively lower
portion of female patients in high-risk group than inter-
mediate and low-risk groups (9.4% Vs 46.7% and 48.7%)
may have affected results in the high-risk group after
FA. We analyzed eGFR in addition to SCr, as SCr
values can vary with age, muscle mass, and sex. Both
SCr and eGFR remained unchanged after FA regardless
of baseline SCr levels, coexisting comorbidities, and
inpatient/outpatient status.
CIN has been investigated mainly in the field of cardiology
and radiology. CIN occurs in 5.2–33% of patients undergo-
ing cardiac catheterization [24] and 4–12% of patients
undergoing a contrast-enhanced CT scan [20, 25–28]. The
rate of 1.3% found in the present study appeared to be
significantly lower compared to CIN associated with cardiac
catheterization and contrast CT scans. Intra-arterial admin-
istration of contrast media, higher dosage, and the invasive
Table 1 Demographic Information, SCr Levels, and eGFR for Patients with Presumed Risk of Developing Acute Kidney Injury
Group Total Low risk Intermediate risk High risk
Number 160 113 15 32
Age 52.46 ± 17.81 51.76 ± 18.84 54.87 ± 14.28 53.78 ± 15.64
Sex (M/F) 91/69 55/58 7/8 29/3
Pre-SCr (mg/dL) 1.52 ± 1.31 0.90 ± 0.27 1.60 ± 0.11 3.64 ± 1.59
Post-SCr (mg/dL) 1.51 ± 1.28 0.93 ± 0.32 1.63 ± 0.26 3.53 ± 1.60
p value 0.93 0.13 0.65 0.04*
Pre-eGFR (mL/min/1.73 m2) 67.02 ± 36.62 84.47 ± 29.71 41.81 ± 6.77 21.56 ± 8.81
Post-eGFR (mL/min/1.73 m2) 66.41 ± 36.54 83.23 ± 30.69 41.36 ± 6.76 22.93 ± 10.47
p value 0.54 0.37 0.81 0.08
Values are presented as mean ± SD (standard deviation)
*p value < 0.05
Table 2 Changes in Serum Creatinine and eGFR According to Coexisting Conditions
Group DM with nephropathy DM without nephropathy CKD HF
Number 15 61 27 7
Age
median 55 59 53 63
interquartile range 46–66 50–69 42–64 46–68
Sex (M/F) 7/8 35/26 22/5 3/4
Pre-SCr (mg/dL)
median 1.60 1.16 2.84 1.33
interquartile range 1.21–3.20 0.89–1.67 1.50–4.99 0.77–1.49
Post-SCr (mg/dL)
median 1.70 1.20 2.74 1.31
interquartile range 1.27–3.20 0.89–1.74 1.42–4.58 0.84–1.67
p value 1.000 0.131 0.115 0.735
Pre-eGFR (mL/min/1.73 m2)
median 38.68 55.76 24.00 54.94
interquartile range 17.28–49.36 35.84–72.76 13.00–39.00 38.68–79.36
Post-eGFR (mL/min/1.73 m2)
median 36.32 55.88 26.00 58.83
interquartile range 20.00–47.00 31.91–72.68 15.21–47.00 33.91–71.78
p value 0.398 0.170 0.679 0.310
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nature of coronary angiography may explain higher CIN rate
in cardiac catheterization. In FA, fluorescein is injected
intravenously in lower doses.
Another reason for lower CIN rate in FA may be the
difference in the nature of contrast media used. A nonio-
dinated fluorescein with lower molecular weight is used in
FA, whereas iodinated contrast agents that have are
commonly used in CT scans, cardiac angiography, and
other conventional radiographic imaging techniques [29].
Although the exact mechanisms underlying contrast
media nephrotoxicity are unknown, increased vasocon-
strictive forces, decreased local prostaglandin- and nitric
oxide-mediated vasodilatation, toxic effect of free radicals
on renal tubular cells, increased intratubular pressure
secondary to contrast-induced diuresis, increased urinary
viscosity, and tubular obstruction are thought to play roles
in the development of CIN [30]. Relatively high osmolality
and viscosity of iodinated contrast media may be related
to these pathogenic processes [31]. However, whether
contrast media itself plays a causal role in developing
acute kidney injury is controversial [20]. In a recent study,
the incidence of CIN in patients undergoing contrast-
enhanced CT did not differ significantly from that in
patients undergoing nonenhanced CT [32].
Pre-existing renal disease is one of the most important
risk factor for CIN [12]. In the present study, risk
stratification according to baseline SCr levels did not
predict CIN development. Patients with co-existing
diabetic nephropathy and chronic kidney disease showed
no change in SCr and eGFR after FA as well. A conven-
tional risk-stratification scheme based on SCr levels for
renal function may not be an adequate method for patients
undergoing FA. It raises questions as to whether FA is
contraindicated in patients with elevated SCr levels or poor
eGFR, and nephrology consultation before FA is an
absolute necessity. In agreement with our finding, FA
did not deteriorate renal function in patients with
diabetic nephropathy [8]. A prospective randomized
study with a large number of patients would be required
to fully address that question, but the present study
suggested that FA is generally safe in terms of acute renal
injury, even for patients with poor kidney function.
Other risk factors for CIN include diabetes and
congestive heart failure [9]. Neither diabetic patients nor
those with congestive heart failure showed an increase
in SCr or eGFR after FA. Advanced age has been identi-
fied as a risk factor for CIN in many studies [12, 33, 34].
We did not find the association between patient age and
CIN development.
The drawbacks of this study included the small num-
ber of patients and lack of long-term prospective results.
This is the first study to examine CIN associated with
FA, and future larger studies are required to validate our
findings. Due to the retrospective nature of the present
study, the comprehensive analysis on concomitant medi-
cation, especially patients’ own drugs that could have
effects on renal function, could not be performed.
Another limitation was that the majority of the patients
included in the study were inpatients (149 of 160
patients; 93.1%). As inpatients presumably experience a
higher number of comorbid conditions relative to outpa-
tients, the incidence of CIN in everyday clinic may
actually be even lower than that found in the present
study. It must be noted that FA is often performed as an
outpatient clinical procedure. Both cases of CIN in the
present study were found in inpatients.
Conclusions
CIN occurred in 1.3% of patients after FA. This rate was
lower than reported rates after coronary angiography or
Table 3 Changes in Serum Creatinine and eGFR of Inpatients
and Outpatients
Inpatients Outpatients
Number 149 11
Pre-SCr (mg/dL)
median 1.10 0.84
interquartile range 0.80–1.57 0.80–1.00
Post-SCr (mg/dL)
median 1.07 0.81
interquartile range 0.80–1.65 0.70–2.08
p-value 0.993 0.656
Pre-eGFR (mL/min/1.73 m2)
median 63.99 79.87
interquartile range 38.52–89.00 51.54–104.06
Post-eGFR (mL/min/1.73 m2)
median 61.28 82.37
interquartile range 38.64–88.00 32.55–101.53
p-value 0.673 0.859
Table 4 Demographic Information, SCr Levels, and eGFR prior and Subsequent to fluorescein angiography
Patient No. Age Sex Pre-SCr (mg/dL) Post-SCr (mg/dL) Change in SCr (mg/dL) Pre-eGFR (mL/min/1.73 m2) Post-eGFR (mL/min/1.73 m2)
1 53 M 0.84 2.08 1.24 90.0 34.0
2 62 M 1.50 2.30 0.80 50.5 30.8
SCr: serum creatinine
eGFR: estimated glomerular filtration rate
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contrast-enhanced CT. The use of a noniodinated agent,
lower dosage, and an intravenous route of administration
may account for the lower incidence of CIN associated
with FA. All patients with CIN displayed normal SCr
levels within 10 days without the need for hemodialysis,
and did not show significant sequelae thereafter. SCr
levels and eGFR remained unchanged after FA regardless
of basline renal function and comorbidities. FA appeared
to be generally safe in terms of acute renal injury.
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